{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:56Z","timestamp":1790349056891,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtha.2024.10.033","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T23:38:49Z","timestamp":1732059529000},"page":"745-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of antithrombotic therapy in patients with hemophilia: a\u00a0selected synopsis of the European Hematology Association\u00a0-\u00a0International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied\u00a0Disorders - European Stroke Organization Clinical Practice Guidance document"],"prefix":"10.1016","volume":"23","author":[{"given":"Miguel","family":"Escobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Bekdache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Owaidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.10.033_bib1","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance","volume":"7","author":"Schutgens","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2024.10.033_bib2","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/hae.12596","article-title":"Cardiovascular disease prevalence and relevance in haemophilia: a scoping review","volume":"21","author":"Rizwan","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.033_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1538-7836.2007.02861.x","article-title":"Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype","volume":"6","author":"Trossa\u00ebrt","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.033_bib4","first-page":"547","article-title":"Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability","volume":"88","author":"Chantarangkul","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.033_bib5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists","volume":"15","author":"de Koning","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.033_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjh.14084","article-title":"Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists","volume":"174","author":"Fitzmaurice","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.033_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/hae.14167","article-title":"Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.033_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A\u00a0first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.033_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0040-1718410","article-title":"Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the French registry","volume":"121","author":"Guillet","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.033_bib10","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2024.10.033_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10557-021-07232-9","article-title":"Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"37","author":"Xu","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jtha.2024.10.033_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis","volume":"41","author":"Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jtha.2024.10.033_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International\u00a0Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.033_bib14","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2019-01-846048","article-title":"How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism","volume":"133","author":"Chan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.033_bib15","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","article-title":"Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies","volume":"18","author":"Coppola","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.033_bib16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/hae.14161","article-title":"Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis","volume":"26","author":"Verstraete","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.033_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.033_bib18","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke","volume":"374","author":"Amarenco","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.033_bib19","doi-asserted-by":"crossref","first-page":"VI","DOI":"10.1177\/23969873211027006","article-title":"European stroke organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA","volume":"6","author":"Dawson","year":"2021","journal-title":"Eur Stroke J"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:11:45Z","timestamp":1762549905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624006858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1538783624006858"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.033","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antithrombotic therapy in patients with hemophilia: a\u00a0selected synopsis of the European Hematology Association\u00a0-\u00a0International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied\u00a0Disorders - European Stroke Organization Clinical Practice Guidance document","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}